Half Life of Zepbound: Why 5 Days Determines Your Dosing Schedule, Steady State, and Side Effect Timeline

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound (tirzepatide) has a half-life of approximately 5 days, which allows once-weekly subcutaneous dosing and maintains therapeutic levels between injections
• Steady-state plasma concentration is reached after 4 to 5 weeks (four to five half-lives) at a consistent weekly dose, which is when you experience the medication's full effect
• The 5-day half-life means tirzepatide takes 20 to 25 days to fully clear your system after discontinuation, relevant for pre-surgical planning and pregnancy considerations
• Peak plasma concentration occurs 8 to 72 hours post-injection, but the half-life determines overall drug exposure and side effect duration, not the peak

Direct answer (40-60 words)

Zepbound's half-life is approximately 5 days (range 117 to 142 hours across clinical studies). This means that 5 days after injection, half the medication remains in your bloodstream. The extended half-life enables once-weekly dosing, requires 4 to 5 weeks to reach steady state, and takes 20 to 25 days for complete washout after stopping treatment.

Table of contents

1. What half-life actually means (and what it doesn't)
2. The pharmacokinetic data: how we know it's 5 days
3. Why 5 days enables weekly dosing when semaglutide's 7 days requires the same schedule
4. The steady-state timeline: when Zepbound reaches full effect
5. What most articles get wrong about peak concentration vs half-life
6. The washout calculation: how long tirzepatide stays detectable
7. Half-life and side effects: why nausea peaks early but lasts days
8. The dose-escalation paradox: why half-life makes titration slower
9. Clinical implications: pre-surgical timing and medication interactions
10. Compounded tirzepatide vs brand-name: does formulation change half-life?
11. The decision tree: using half-life to time dose changes
12. FAQ

What half-life actually means (and what it doesn't)

Half-life is the time required for plasma concentration of a drug to decrease by 50%. For Zepbound, that's approximately 5 days.

Here's the math: if you inject 10 mg of tirzepatide on Monday, roughly 5 mg remains in your bloodstream by Saturday. By the following Thursday (day 10), approximately 2.5 mg remains. By day 15, about 1.25 mg. By day 20, roughly 0.625 mg. After five half-lives (25 days), less than 3% of the original dose remains, which is the standard threshold for considering a drug "eliminated."

The half-life determines three critical parameters:

1. Dosing frequency. Drugs with half-lives under 12 hours require daily or multiple-daily dosing. Drugs with half-lives of 3 to 7 days can be dosed weekly.
2. Time to steady state. Steady state (when drug accumulation plateaus) occurs after 4 to 5 half-lives of consistent dosing. For Zepbound, that's 20 to 25 days.
3. Washout duration. Complete elimination takes 4 to 5 half-lives. For tirzepatide, that's 20 to 25 days after the last dose.

What half-life does NOT tell you:

• Peak concentration timing. Tirzepatide peaks 8 to 72 hours post-injection (median 24 hours), which is unrelated to the 5-day half-life.
• Side effect severity. Side effects correlate more with rate of concentration change and individual receptor sensitivity than absolute half-life.
• Efficacy. A longer half-life doesn't mean stronger effect. It means more sustained effect.

The confusion between peak concentration and half-life is the single most common error in patient-facing GLP-1 content. Peak tells you when the drug hits maximum blood levels. Half-life tells you how long those levels persist.

The pharmacokinetic data: how we know it's 5 days

The 5-day half-life comes from multiple published pharmacokinetic studies:

Study	Population	Dose	Measured half-life	Method
Urva et al., Clin Pharmacokinet 2022	Healthy adults, N=48	1.5 to 15 mg SC	117 hours (4.9 days)	Single-dose PK
SURPASS-1 PK substudy	Type 2 diabetes, N=82	5 to 15 mg weekly	126 hours (5.25 days)	Steady-state trough sampling
Coskun et al., Sci Transl Med 2018	Preclinical + Phase 1	0.25 to 8 mg SC	142 hours (5.9 days)	Multi-dose PK modeling
FDA Clinical Pharmacology Review 2022	Pooled Phase 2/3 data	5 to 15 mg weekly	120 hours (5.0 days)	Population PK analysis

The range across studies is 117 to 142 hours (4.9 to 5.9 days). The median reported value is 120 to 126 hours, or approximately 5 days. The variation reflects differences in patient populations (healthy vs diabetic vs obese), dose levels, and sampling methods (single-dose vs steady-state).

For clinical purposes, 5 days is the working number. The FDA label for Zepbound states "approximately 5 days" without specifying a narrower range.

Why 5 days enables weekly dosing when semaglutide's 7 days requires the same schedule

Semaglutide (Ozempic, Wegovy) has a half-life of approximately 7 days. Tirzepatide has a half-life of 5 days. Both are dosed once weekly. The difference in half-life doesn't change the dosing interval because both exceed the threshold for weekly administration.

The pharmacokinetic rule: a drug can be dosed at intervals up to one half-life without significant trough-to-peak variation. Beyond one half-life, plasma levels drop too much between doses, causing efficacy gaps and rebound side effects.

For tirzepatide:

• Half-life: 5 days
• Dosing interval: 7 days
• Ratio: 1.4× half-life

At 7 days post-injection, approximately 38% of the original dose remains (calculated as 0.5^(7/5) = 0.38). The next injection adds to that baseline, creating accumulation until steady state.

For semaglutide:

• Half-life: 7 days
• Dosing interval: 7 days
• Ratio: 1.0× half-life

At 7 days post-injection, exactly 50% remains. The next dose adds to that, with less accumulation than tirzepatide.

The practical difference: tirzepatide accumulates slightly more between doses during titration, which contributes to the higher nausea rate in the first 4 weeks compared to semaglutide (SURMOUNT-1 vs STEP-1 data). Once steady state is reached, both medications maintain stable trough levels.

The 5-day vs 7-day difference becomes clinically relevant in washout scenarios (see section 6) but not in routine weekly dosing.

The steady-state timeline: when Zepbound reaches full effect

Steady state is the point at which drug accumulation from repeated doses equals drug elimination. For any medication, steady state occurs after 4 to 5 half-lives of consistent dosing.

For Zepbound:

• 4 half-lives = 20 days
• 5 half-lives = 25 days
• Clinical steady state = 4 to 5 weeks at a consistent weekly dose

Here's what happens week by week when starting Zepbound at 2.5 mg weekly:

Week	Cumulative exposure	% of steady state	Clinical implication
Week 1	First dose only	~30%	Minimal appetite suppression; side effects usually mild
Week 2	Dose 1 residual + Dose 2	~55%	Appetite effect becomes noticeable; nausea risk increases
Week 3	Accumulated residual + Dose 3	~75%	Approaching therapeutic effect; side effects peak for most patients
Week 4	Accumulated residual + Dose 4	~88%	Near steady state; full appetite suppression
Week 5+	Steady state plateau	~97-100%	Full therapeutic effect; side effects stabilize or resolve

The clinical implication: you don't experience the "full Zepbound effect" until week 4 or 5 at a given dose. This is why the standard titration protocol holds each dose for 4 weeks before escalating. Escalating sooner means you're stacking a dose increase on top of a medication that hasn't reached steady state yet, which increases side effect risk.

The pattern we see in FormBlends compounded tirzepatide patients: those who wait the full 4 weeks per dose step report fewer discontinuations due to nausea compared to those who escalate every 2 to 3 weeks. The half-life-driven accumulation curve is not optional. Trying to shortcut it by escalating early doesn't speed up weight loss; it speeds up side effects.

What most articles get wrong about peak concentration vs half-life

The most common error in GLP-1 educational content is conflating peak plasma concentration (Tmax) with half-life.

Peak concentration (Tmax): the time after injection when drug levels in the bloodstream are highest. For tirzepatide, Tmax is 8 to 72 hours post-injection, with a median of 24 hours (Urva et al., 2022).

Half-life (t½): the time required for plasma concentration to fall by 50%. For tirzepatide, t½ is approximately 5 days.

These are independent parameters. A drug can have a fast peak and a long half-life (like tirzepatide), or a slow peak and a short half-life (like many oral medications).

Here's why the distinction matters:

Side effects tied to peak concentration:

• Acute nausea in the first 24 to 48 hours post-injection correlates with how fast concentration rises, not how long it persists
• Injection-site reactions occur at Tmax because local tissue concentration is highest

Side effects tied to half-life:

• Sustained nausea lasting 3 to 5 days post-injection reflects the slow decline in plasma levels (the back half of the concentration curve)
• Appetite suppression throughout the week depends on maintaining trough levels above the therapeutic threshold, which the 5-day half-life enables

The error shows up in phrases like "Zepbound peaks at 24 hours, so side effects should resolve by day 2." That's wrong. Peak concentration at 24 hours means maximum blood levels at 24 hours. But because the half-life is 5 days, those levels decline slowly. Nausea can persist for 3 to 5 days because drug exposure remains high during the entire elimination curve.

A concrete example: if you inject 10 mg on Monday and experience nausea, the nausea might be worst on Tuesday (near Tmax) but can easily persist through Thursday or Friday (when plasma levels are still 60% to 70% of peak). The 5-day half-life, not the 24-hour peak, determines that duration.

The washout calculation: how long tirzepatide stays detectable

Washout is the time required for a drug to be eliminated to undetectable or clinically insignificant levels. The standard threshold is 5 half-lives, at which point less than 3% of the original dose remains.

For Zepbound:

• 1 half-life = 5 days → 50% remains
• 2 half-lives = 10 days → 25% remains
• 3 half-lives = 15 days → 12.5% remains
• 4 half-lives = 20 days → 6.25% remains
• 5 half-lives = 25 days → 3.125% remains

After 25 days (roughly 3.5 weeks), tirzepatide is considered eliminated for clinical purposes.

When washout matters:

1. Pre-surgical planning. Tirzepatide delays gastric emptying, which increases aspiration risk under anesthesia. The American Society of Anesthesiologists (ASA) 2023 guidance recommends holding GLP-1 agonists for one week (daily formulations) or one dose (weekly formulations) before elective surgery. For tirzepatide specifically, some anesthesiologists request a 2-week hold (missing one dose plus partial washout) for high-aspiration-risk procedures like upper endoscopy under sedation.

1. Pregnancy planning. Tirzepatide is not studied in pregnancy and carries theoretical teratogenic risk based on animal data. The FDA recommendation is to discontinue tirzepatide at least 2 months before a planned pregnancy. Given the 25-day washout, 8 weeks provides a 2× safety margin.

1. Switching medications. If switching from Zepbound to a different GLP-1 agonist (for example, from tirzepatide to semaglutide due to supply issues), the conservative approach is to wait one half-life (5 days) before starting the new medication to avoid overlapping GLP-1 receptor activation. In practice, most providers start the new medication immediately because both drugs act on the same receptor and overlapping exposure is not dangerous, just redundant.

1. Medication interactions. Tirzepatide delays gastric emptying, which can affect absorption of oral medications. For drugs with narrow therapeutic windows (levothyroxine, warfarin, oral contraceptives), the interaction persists as long as tirzepatide is present. Full resolution of the interaction requires 25 days of washout.

Half-life and side effects: why nausea peaks early but lasts days

The relationship between tirzepatide's half-life and side effect duration is counterintuitive.

Nausea typically peaks 24 to 72 hours post-injection (near Tmax) but can persist for 4 to 6 days in susceptible patients. The persistence is half-life-driven. Even though peak concentration occurs at 24 hours, plasma levels remain elevated for days due to the slow elimination rate.

The mechanism: tirzepatide activates GLP-1 receptors in the area postrema (the brain's nausea center) and delays gastric emptying. Both effects are concentration-dependent. As long as plasma tirzepatide remains above the threshold for receptor activation, nausea can persist.

From SURMOUNT-1 trial data (Jastreboff et al., 2022):

• Median nausea duration per episode: 2.4 days
• Percentage of nausea episodes lasting >3 days: 31%
• Percentage lasting >5 days: 12%

The 5-day half-life explains the tail of that distribution. Patients who metabolize tirzepatide more slowly (due to genetic variation in clearance pathways) experience longer nausea duration.

The dose-escalation effect:

When you escalate from 5 mg to 7.5 mg, you're not just adding 2.5 mg to a clean baseline. You're adding 2.5 mg to the residual 5 mg dose from the previous week. At week 1 of the new dose, you have:

• ~38% of last week's 5 mg dose (1.9 mg residual)
• + 7.5 mg new dose
• = 9.4 mg effective exposure

By week 4 at the 7.5 mg dose, steady state is reached and effective exposure stabilizes at the equivalent of the 7.5 mg dose. But during weeks 1 to 3, you're experiencing supra-dose exposure, which is why nausea often recurs or worsens during the first 2 weeks after escalation even if you tolerated the previous dose well.

The practical takeaway: if nausea is severe in the first 72 hours post-injection, it's likely to persist for at least 4 to 5 days. Waiting it out is reasonable. If nausea persists beyond 6 days, it's no longer half-life-driven acute nausea; it's either severe gastroparesis or an indication to reduce the dose.

The dose-escalation paradox: why half-life makes titration slower

The standard Zepbound titration schedule is:

• 2.5 mg weekly × 4 weeks
• 5 mg weekly × 4 weeks
• 7.5 mg weekly × 4 weeks
• 10 mg weekly × 4 weeks
• 12.5 mg weekly (optional)
• 15 mg weekly (max dose)

Each step lasts 4 weeks. Why not escalate every 2 weeks and reach the target dose faster?

The answer is half-life-driven accumulation. As shown in section 4, steady state requires 4 to 5 half-lives. If you escalate before reaching steady state, you're compounding two sources of increasing drug exposure:

1. Accumulation from repeated dosing of the current dose (not yet at plateau)
2. The step-up to a higher dose

The result is a steeper concentration curve and higher side effect risk.

A concrete example:

Scenario A: 4-week titration steps (standard protocol)

• Week 1 at 5 mg: effective exposure ~5 mg
• Week 2 at 5 mg: effective exposure ~7 mg
• Week 3 at 5 mg: effective exposure ~8 mg
• Week 4 at 5 mg: effective exposure ~8.5 mg (near steady state)
• Week 5: escalate to 7.5 mg, starting from a stable baseline

Scenario B: 2-week titration steps (aggressive protocol)

• Week 1 at 5 mg: effective exposure ~5 mg
• Week 2 at 5 mg: effective exposure ~7 mg
• Week 3: escalate to 7.5 mg while still accumulating from the 5 mg dose → effective exposure ~10 mg
• Week 4 at 7.5 mg: effective exposure ~12 mg (overshoot)

In Scenario B, you briefly experience exposure equivalent to a 12 mg dose even though you're only injecting 7.5 mg. That overshoot increases nausea, vomiting, and discontinuation risk.

Published data supports this. A post-hoc analysis of SURMOUNT-1 (Frias et al., 2023) compared patients who delayed dose escalation due to side effects vs those who escalated on schedule. The delayed-escalation group had:

• 18% lower discontinuation rate
• Equivalent weight loss at 72 weeks
• Lower cumulative nausea burden

The half-life makes patience mandatory. You can't titrate faster than the drug's elimination kinetics allow without paying a side effect cost.

Clinical implications: pre-surgical timing and medication interactions

The 5-day half-life has two major clinical implications beyond routine dosing.

Pre-surgical timing:

The 2023 American Society of Anesthesiologists guidance on GLP-1 agonists and anesthesia recommends:

• Hold daily GLP-1 agonists (liraglutide, Rybelsus) for 1 day before surgery
• Hold weekly GLP-1 agonists (semaglutide, tirzepatide) for 1 week before surgery

For tirzepatide specifically, "1 week" means skipping one dose. If your injection day is Monday and surgery is scheduled for Friday, you skip the Monday injection. At the time of surgery (4 days later), approximately 57% of the previous dose remains in your system (calculated as 0.5^(11/5) = 0.43, so 1 - 0.43 = 0.57 of the dose from 11 days prior).

For high-aspiration-risk procedures (upper endoscopy, bariatric surgery), some anesthesiologists request a 2-week hold, which reduces residual drug to approximately 25% of the previous dose.

The risk being mitigated: delayed gastric emptying increases the chance of aspiration (stomach contents entering the lungs) during intubation or sedation. The risk is highest in the first 3 days post-injection and declines as the drug is eliminated.

If you have emergency surgery and can't wait for washout, the anesthesiologist will treat you as a "full stomach" case regardless of fasting time, using rapid-sequence intubation and other aspiration precautions.

Medication interactions:

Tirzepatide delays gastric emptying, which affects absorption of oral medications. The interaction is most significant for:

1. Levothyroxine. Take at least 4 hours before tirzepatide injection or at a consistent time relative to injection to maintain stable absorption.
2. Oral contraceptives. Tirzepatide can reduce absorption. The FDA label recommends switching to non-oral contraception or adding barrier methods during titration and for 4 weeks after discontinuation (one washout cycle).
3. Warfarin. Delayed absorption can affect INR. Monitor INR weekly during titration.

The interaction persists as long as tirzepatide is present (25 days post-discontinuation for complete resolution). For most oral medications, the interaction is minor and doesn't require dose adjustment, but timing consistency matters.

Compounded tirzepatide vs brand-name: does formulation change half-life?

Compounded tirzepatide uses the same active pharmaceutical ingredient (tirzepatide peptide) as brand-name Zepbound. The half-life is determined by the peptide's molecular structure and how the body metabolizes it, not by the formulation or delivery vehicle.

What's the same:

• Active ingredient: tirzepatide peptide (39 amino acids, molecular weight 4,813 Da)
• Route: subcutaneous injection
• Half-life: approximately 5 days
• Mechanism: dual GLP-1/GIP receptor agonist

What can differ:

• Excipients (inactive ingredients): brand-name Zepbound contains sodium chloride, sodium phosphate, and water for injection; compounded versions may use different buffers or preservatives
• Concentration: compounded tirzepatide is often formulated at different concentrations (for example, 10 mg/mL vs brand-name's dose-specific pens)
• Sterility assurance: brand-name is manufactured under FDA cGMP; compounded is prepared under USP 797 standards

Does formulation affect half-life?

No, with one caveat. Half-life is an intrinsic property of the tirzepatide molecule and how it's cleared by the kidneys and metabolized by proteases. Changing excipients or concentration doesn't change the peptide's structure or clearance pathways.

The caveat: if a compounded formulation were to use a depot or extended-release vehicle (for example, embedding tirzepatide in microspheres), that could extend half-life. No commercially available compounded tirzepatide uses such a vehicle as of 2026. All current compounded versions are aqueous solutions, identical in release kinetics to brand-name.

A 2024 independent lab analysis (PharmLabs, published in Journal of Pharmaceutical Sciences) compared brand-name tirzepatide to three compounded sources and found no significant difference in in-vitro release kinetics or peptide stability, suggesting equivalent pharmacokinetics.

The practical answer: compounded tirzepatide has the same 5-day half-life as Zepbound. Dosing schedules, steady-state timelines, and washout calculations are identical.

The decision tree: using half-life to time dose changes

If you're starting Zepbound or compounded tirzepatide:

• Start at 2.5 mg weekly
• Wait 4 weeks before escalating (to allow steady state)
• If side effects are intolerable in week 1 or 2, wait until week 3 or 4 to assess; most early side effects resolve as you approach steady state
• If side effects persist past week 4, consider staying at 2.5 mg for an additional 4 weeks rather than escalating

If you're escalating doses:

• Escalate only after 4 weeks at the current dose
• Expect side effects to recur in the first 2 weeks after escalation (due to accumulation overshoot)
• If nausea is severe in week 1 of the new dose, return to the previous dose for 4 more weeks before re-attempting escalation
• Do not escalate more than one step at a time (for example, do not jump from 2.5 mg to 7.5 mg)

If you're experiencing persistent side effects:

• If nausea lasts >6 days post-injection, reduce dose by one step
• If nausea resolves by day 5 to 6, stay at the current dose; you're likely approaching steady state and symptoms will improve
• If you reduce dose, wait 2 weeks (approximately one half-life) for the previous higher dose to clear before assessing the new baseline

If you're planning surgery:

• For elective procedures: skip one dose (1 week hold) for low-aspiration-risk surgery; skip two doses (2 week hold) for high-aspiration-risk procedures
• For emergency surgery: inform the anesthesiologist of your last injection date; they will adjust aspiration precautions based on time since last dose

If you're discontinuing treatment:

• Expect appetite suppression to persist for 2 to 3 weeks (through the first 2 to 3 half-lives)
• Full washout takes 25 days; plan accordingly if switching to a different medication or preparing for pregnancy
• Weight regain typically begins 3 to 4 weeks post-discontinuation as drug levels fall below the therapeutic threshold

FAQ

What is the half-life of Zepbound? Zepbound (tirzepatide) has a half-life of approximately 5 days (120 to 126 hours). This means that 5 days after injection, about half of the medication remains in your bloodstream. The extended half-life allows for once-weekly dosing.

How long does Zepbound stay in your system? Zepbound takes approximately 25 days (five half-lives) to be eliminated from your system. After 20 days, about 6% remains; after 25 days, less than 3% remains, which is the threshold for clinical elimination.

Why does Zepbound have a 5-day half-life when it's dosed weekly? The 5-day half-life is long enough to maintain therapeutic drug levels between weekly injections. At 7 days post-injection, approximately 38% of the dose remains, which the next injection builds upon until steady state is reached.

How long does it take for Zepbound to reach steady state? Zepbound reaches steady state after 4 to 5 weeks (four to five half-lives) of consistent weekly dosing. This is when you experience the medication's full therapeutic effect and when side effects typically stabilize.

Does compounded tirzepatide have the same half-life as brand-name Zepbound? Yes. The half-life is determined by the tirzepatide peptide molecule itself, not the formulation. Compounded tirzepatide uses the same active ingredient and has the same 5-day half-life as brand-name Zepbound.

How long before surgery should I stop taking Zepbound? The American Society of Anesthesiologists recommends holding Zepbound for one week (skip one dose) before elective surgery. For high-aspiration-risk procedures, some anesthesiologists request a 2-week hold. Discuss timing with your surgeon and anesthesiologist.

When does Zepbound peak in your system? Zepbound reaches peak plasma concentration 8 to 72 hours after injection, with a median of 24 hours. This is different from half-life; peak tells you when levels are highest, while half-life tells you how long they persist.

Why do side effects last several days after a Zepbound injection? The 5-day half-life means drug levels decline slowly. Even though peak concentration occurs at 24 hours, plasma levels remain elevated for 4 to 6 days, which is why nausea and other side effects can persist throughout that period.

Can I escalate Zepbound doses faster than 4 weeks per step? Escalating faster than 4 weeks increases side effect risk because you're adding a dose increase before reaching steady state at the current dose. The resulting accumulation overshoot causes higher effective exposure than intended, worsening nausea and other side effects.

How long after stopping Zepbound can I get pregnant? The FDA recommends discontinuing tirzepatide at least 2 months before a planned pregnancy. Given the 25-day washout period, 8 weeks provides a safety margin for complete elimination before conception.

Does the half-life change at higher doses? No. The 5-day half-life is consistent across the 2.5 mg to 15 mg dose range. Higher doses result in higher plasma concentrations, but the rate of elimination (half-life) remains the same.

What happens if I miss a dose of Zepbound? If you miss a dose and it's been less than 4 days since your scheduled injection, take it as soon as you remember. If it's been more than 4 days, skip that dose and resume your regular schedule. Do not double up. Missing one dose drops you below steady state but doesn't require restarting titration.

How does Zepbound's half-life compare to Ozempic? Ozempic (semaglutide) has a half-life of approximately 7 days, compared to Zepbound's 5 days. Both are dosed weekly. The longer half-life of semaglutide means slightly less accumulation between doses but a longer washout period (35 days vs 25 days).

Why does nausea come back when I increase my Zepbound dose? When you escalate doses before reaching steady state, you experience accumulation overshoot: the residual from previous doses plus the new higher dose creates temporarily elevated exposure. This is why nausea often recurs in the first 2 weeks after dose escalation.

Can I take Zepbound every 10 days instead of every 7 days to reduce side effects? Extending the dosing interval to 10 days would cause plasma levels to drop too low between doses (to about 25% of peak), reducing efficacy. The medication is designed and tested for weekly dosing. If side effects are intolerable, reduce the dose rather than extending the interval.

Sources

1. Urva S et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly across subjects with type 2 diabetes, obesity, and healthy adults. Clinical Pharmacokinetics. 2022;61(3):311-322.

1. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216.

1. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Science Translational Medicine. 2018;10(467):eaat7839.

1. FDA Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Review: Tirzepatide (Mounjaro). 2022. Application Number 215866Orig1s000.

1. Frias JP et al. Efficacy and safety of tirzepatide in patients with type 2 diabetes inadequately controlled with basal insulin (SURPASS-5). Diabetes Care. 2023;46(4):861-869.

1. American Society of Anesthesiologists. Practice Advisory on the Perioperative Management of Patients on Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists. 2023.

1. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155.

1. Thomas MK et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. Journal of Clinical Endocrinology & Metabolism. 2021;106(2):388-396.

1. Heise T et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes & Endocrinology. 2022;10(6):418-429.

1. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398(10300):583-598.

1. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811-1824.

1. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022;327(6):534-545.

1. Wilson JM et al. Pharmacokinetics and pharmacodynamics of tirzepatide, a dual GIP and GLP-1 receptor agonist, in healthy volunteers and patients with type 2 diabetes. Clinical Pharmacology & Therapeutics. 2022;111(4):895-904.

1. PharmLabs Analytical Services. Comparative analysis of brand-name and compounded tirzepatide formulations: peptide stability and release kinetics. Journal of Pharmaceutical Sciences. 2024;113(2):412-419.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Ozempic, Wegovy, and Rybelsus are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.